Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070420 | 1.00 | EPHX1 (0.48) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL9264620 | 1.00 | EPHX1 (0.48) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL6919663 | 1.00 | EPHX1 (0.48) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL6069547 | 1.00 | EPHX1 (0.48) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL28633045 | 0.98 | EPHX1 (0.47) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL15307543 | 0.83 | EPHX1 (0.67) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL3343090 | 0.83 | EPHX1 (0.67) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL6689012 | 0.83 | EPHX1 (0.67) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL9458781 | 0.83 | EPHX1 (0.67) | EPHX1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL2533818 | 0.83 | EPHX1 (0.67) | EPHX1MEN1KMT2ATP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056947-B2 | For inhibiting (cysteine) proteases/caspases; for treatment of viral infections, stroke, neurodegenerative disease, and inflammatory diseases | GEORGIA TECH RESEARCH CORP. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040048327-A1 | Aza-peptide epoxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-11 | — | — | US | disclosed |
| EP-0157327-B1 | NOVEL COMPOUNDS FOR DETECTING THE PRESENCE OF HYDROLYTIC ANALYTES IN A TEST SAMPLE | MILES INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| EP-0158204-B1 | COMPOSITION AND TEST DEVICE FOR DETERMINING THE PRESENCE OF LEUKOCYTES, CONTAINING A ZWITTERION COUPLING AGENT | MILES INC. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0157326-B1 | COMPOSITION AND TEST DEVICE FOR DETERMINING THE PRESENCE OF LEUKOCYTES, ESTERASE AND PROTEASE IN A TEST SAMPLE | MILES INC. (US) | 1989-05-31 | — | — | EP | disclosed |
| US-4774340-A | AMINATION, CYCLIZATION, ESTERIFICATION | MILES INC. (US) | 1988-09-27 | — | — | US | disclosed |
| US-4716236-A | Method for synthesizing esters | MILES LABORATORIES, INC. (US) | 1987-12-29 | — | — | US | disclosed |
| US-4704460-A | LEUKOCYTES IN URINE | MILES LABORATORIES, INC. (US) | 1987-11-03 | — | — | US | disclosed |
| US-4657855-A | DIP-AND-READ, UROGENITAL DISORDERS | MILES LABORATORIES, INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4645842-A | DETECTING LEUKOCYTES TO INDICATE KIDNEY OR UROGENITAL DISORDERS | MILES LABORATORIES, INC. (US) | 1987-02-24 | — | — | US | disclosed |
| US-4637979-A | Composition and test device for determining the presence of leukocytes containing a zwitterion coupling agent | MILES LABORATORIES, INC. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0158204-A2 | Composition and test device for determining the presence of leukocytes, containing a zwitterion coupling agent | MILES INC. (US) | 1985-10-16 | — | — | EP | disclosed |
| EP-0158226-A2 | Method of synthesizing esters | MILES INC. (US) | 1985-10-16 | — | — | EP | disclosed |
| EP-0157327-A2 | Novel compounds for detecting the presence of hydrolytic analytes in a test sample | MILES INC. (US) | 1985-10-09 | — | — | EP | disclosed |
| EP-0157326-A2 | Composition and test device for determining the presence of leukocytes, esterase and protease in a test sample | MILES INC. (US) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048327-A1 | Aza-peptide epoxides | ANPEP, ENPEP, TMPRSS15 | EPHX1 13/4885MEN1 3405/4885KMT2A 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.